Sai Parenterals Q4 FY26 Revenue Surges 166% to ₹197.93 Cr; PAT Jumps 736%
Sai Parenterals Limited reported Q4 FY26 consolidated revenue of ₹197.93 crore, up 166.65% YoY, with PAT rising 736.04% to ₹13.25 crore. FY26 revenue reached ₹380.99 crore, up 140.37% YoY, with PAT at ₹14.37 crore. The company completed a ₹285 crore IPO in March 2026 and targets ₹750 crore revenue in FY27.
The substantial financial growth, successful IPO raising significant capital, strategic acquisition, and future growth targets indicate a material positive impact on the company's financial standing and market position.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT for both the quarter and the full year, indicating strong operational performance and financial health. The successful IPO and strategic acquisitions further contribute to a positive outlook.
Sai Parenterals Limited (SPL) has announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company reported a robust performance, driven by CDMO exports and the integration of Noumed (Australia).
For the fourth quarter of FY26, SPL's total income grew by 169.97% year-on-year to ₹200.81 crore, while gross profit increased by 374.3% to ₹76.51 crore. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) surged by 366.79% to ₹28.97 crore, and Profit After Tax (PAT) witnessed a substantial jump of 736.08% to ₹13.25 crore.
On a full-year basis for FY26, total income rose by 144.78% to ₹389.51 crore, with gross profit growing by 125.6% to ₹147.29 crore. EBITDA increased by 33.29% to ₹47.21 crore, and PAT grew by 45.52% to ₹14.37 crore.
Standalone performance for FY26 showed revenue growth of 30.65% year-on-year to ₹164.99 crore, with EBITDA up by 22.63% to ₹33.32 crore and PAT increasing by 63.61% to ₹16.86 crore. The acquisition of a 74.6% controlling stake in Noumed (Australia) on November 12, 2025, has strengthened SPL's position in the Australian market.
The company successfully completed its Initial Public Offering (IPO) in March 2026, raising ₹285 crore, and was listed on April 02, 2026. Allocated funds include ₹130 crore for capacity expansion, manufacturing facility upgrades, and a new R&D center in India.
SPL is undertaking a significant capex program, including capacity expansion and EU-GMP upgradation at its Indian facilities (₹118 crore), construction of Australia's largest pharmaceutical plant (AUD 53 million, backed by AUD 20 million grant, completion in Q4FY27), and establishment of a dedicated R&D center (₹18 crore). These projects are expected to be completed by FY27.
Mr. Anil Kumar Karusala, Managing Director, expressed optimism, stating, "We target to achieve ₹750 crore revenue for FY27 and EBITDA margins of 17%." He highlighted the strong IP-led approach, significant CDMO revenue growth, and the ongoing capex-led expansion positioning the company for its next phase of growth.
What to do with a filing like this
Sai Parenterals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sai Parenterals Limited. Read the original for the full detail.